Mercer Global Advisors Inc Exelixis, Inc. Transaction History

Mercer Global Advisors Inc

$40.5 Billion
Q4 2024

A detailed history of Mercer Global Advisors Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Mercer Global Advisors Inc holds 46,221 shares of EXEL stock, worth $1.67 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

46,221

Previous 48,402 4.51%

Holding current value

$1.67 Million

Previous $1.26 Million 22.53%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$25.39 - $36.46 $55,375 - $79,519	-2,181 Reduced 4.51%	46,221 $1.54 Million
Q3 2024 Nov 13, 2024	BUY	$21.96 - $27.6 $38,693 - $48,631	1,762 Added 3.78%	48,402 $1.26 Million
Q2 2024 Aug 12, 2024	SELL	$20.34 - $23.73 $7,220 - $8,424	-355 Reduced 0.76%	46,640 $1.05 Million
Q1 2024 May 15, 2024	BUY	$20.17 - $23.93 $67,670 - $80,285	3,355 Added 7.69%	46,995 $1.12 Million
Q4 2023 Feb 14, 2024	SELL	$19.25 - $24.13 $107,357 - $134,573	-5,577 Reduced 11.33%	43,640 $1.05 Million
Q3 2023 Nov 13, 2023	BUY	$19.04 - $22.74 $228,042 - $272,356	11,977 Added 32.16%	49,217 $1.08 Million
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $85,526 - $96,399	4,707 Added 14.47%	37,240 $711,000
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $64,711 - $77,057	3,970 Added 13.9%	32,533 $631,000
Q4 2022 Feb 08, 2023	SELL	$14.96 - $17.39 $116,837 - $135,815	-7,810 Reduced 21.47%	28,563 $458,000
Q3 2022 Nov 15, 2022	SELL	$15.68 - $22.27 $33,272 - $47,256	-2,122 Reduced 5.51%	36,373 $570,000
Q2 2022 Aug 10, 2022	BUY	$17.44 - $23.16 $124,940 - $165,918	7,164 Added 22.87%	38,495 $801,000
Q1 2022 May 10, 2022	BUY	$17.03 - $22.67 $150,323 - $200,108	8,827 Added 39.22%	31,331 $710,000
Q4 2021 Feb 04, 2022	SELL	$15.84 - $21.88 $64,215 - $88,701	-4,054 Reduced 15.26%	22,504 $411,000
Q3 2021 Nov 10, 2021	SELL	$16.3 - $21.14 $107,726 - $139,714	-6,609 Reduced 19.93%	26,558 $561,000
Q2 2021 Aug 10, 2021	SELL	$17.95 - $25.56 $68,102 - $96,974	-3,794 Reduced 10.26%	33,167 $604,000
Q1 2021 May 11, 2021	SELL	$20.53 - $25.22 $414,747 - $509,494	-20,202 Reduced 35.34%	36,961 $835,000
Q4 2020 Feb 12, 2021	SELL	$18.39 - $24.8 $124,389 - $167,747	-6,764 Reduced 10.58%	57,163 $1.15 Million
Q3 2020 Dec 10, 2020	SELL	$20.67 - $26.94 $5,870 - $7,650	-284 Reduced 0.44%	63,927 $1.56 Million
Q2 2020 Aug 10, 2020	SELL	$16.46 - $27.42 $241,698 - $402,635	-14,684 Reduced 18.61%	64,211 $1.52 Million
Q1 2020 May 18, 2020	SELL	$14.46 - $21.8 $2,371 - $3,575	-164 Reduced 0.21%	78,895 $1.36 Million
Q4 2019 Feb 13, 2020	BUY	$15.15 - $18.89 $773,710 - $964,712	51,070 Added 182.46%	79,059 $1.39 Million
Q3 2019 Nov 12, 2019	BUY	$17.68 - $22.65 $143,243 - $183,510	8,102 Added 40.74%	27,989 $494,000
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $39,336 - $51,430	2,078 Added 11.67%	19,887 $425,000
Q1 2019 Apr 23, 2019	SELL	$19.6 - $24.76 $53,253 - $67,272	-2,717 Reduced 13.24%	17,809 $424,000
Q1 2019 Apr 12, 2019	BUY	$19.6 - $24.76 $402,309 - $508,223	20,526 New	20,526 $404,000

Others Institutions Holding EXEL

# of Institutions

569

Shares Held

252M

Call Options Held

1.45M

Put Options Held

1.13M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Mercer Global Advisors Inc , based on Form 13F filings with the SEC.

News

Stay updated on Mercer Global Advisors Inc with notifications on news.

Account

Mercer Global Advisors Inc Exelixis, Inc. Transaction History